Arthur F. Ryan - 01 Mar 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Arthur F. Ryan
Issuer symbol
REGN
Transactions as of
01 Mar 2024
Net transactions value
-$98,205
Form type
4
Filing time
05 Mar 2024, 16:01:49 UTC
Previous filing
05 Feb 2024
Next filing
03 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $968 -1 -0.01% $967.50 18,381 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $969 -1 -0.01% $968.66 18,380 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $969 -1 -0.01% $969.18 18,379 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $3,882 -4 -0.02% $970.38 18,375 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $972 -1 -0.01% $971.75 18,374 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $1,945 -2 -0.01% $972.29 18,372 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $975 -1 -0.01% $974.78 18,371 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $1,951 -2 -0.01% $975.70 18,369 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $1,954 -2 -0.01% $976.81 18,367 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $1,955 -2 -0.01% $977.27 18,365 01 Mar 2024 Direct F1, F2
transaction REGN Common Stock Sale $978 -1 -0.01% $978.09 18,364 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $980 -1 -0.01% $979.87 18,363 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $980 -1 -0.01% $980.21 18,362 01 Mar 2024 Direct F1
transaction REGN Common Stock Sale $14,725 -15 -0.08% $981.64 18,347 01 Mar 2024 Direct F1, F3
transaction REGN Common Stock Sale $10,809 -11 -0.06% $982.67 18,336 01 Mar 2024 Direct F1, F4
transaction REGN Common Stock Sale $11,803 -12 -0.07% $983.61 18,324 01 Mar 2024 Direct F1, F5
transaction REGN Common Stock Sale $18,705 -19 -0.1% $984.45 18,305 01 Mar 2024 Direct F1, F6
transaction REGN Common Stock Sale $9,858 -10 -0.05% $985.76 18,295 01 Mar 2024 Direct F1, F7
transaction REGN Common Stock Sale $7,893 -8 -0.04% $986.58 18,287 01 Mar 2024 Direct F1, F8
transaction REGN Common Stock Sale $3,949 -4 -0.02% $987.33 18,283 01 Mar 2024 Direct F1, F9
transaction REGN Common Stock Sale $988 -1 -0.01% $988.30 18,282 01 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023.
F2 Represents volume-weighted average price of sales of 2 shares of Company stock on March 1, 2024 at prices ranging from $977.00 to $977.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F3 Represents volume-weighted average price of sales of 15 shares of Company stock on March 1, 2024 at prices ranging from $981.09 to $981.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F4 Represents volume-weighted average price of sales of 11 shares of Company stock on March 1, 2024 at prices ranging from $982.51 to $982.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F5 Represents volume-weighted average price of sales of 12 shares of Company stock on March 1, 2024 at prices ranging from $983.21 to $983.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F6 Represents volume-weighted average price of sales of 19 shares of Company stock on March 1, 2024 at prices ranging from $984.00 to $984.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F7 Represents volume-weighted average price of sales of 10 shares of Company stock on March 1, 2024 at prices ranging from $985.26 to $985.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F8 Represents volume-weighted average price of sales of 8 shares of Company stock on March 1, 2024 at prices ranging from $986.45 to $986.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.
F9 Represents volume-weighted average price of sales of 4 shares of Company stock on March 1, 2024 at prices ranging from $987.05 to $987.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2024 at each separate price.